Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors

Summary

The purpose of this phase I/II study is to evaluate the safety and efficacy of 9-ING-41, a potent GSK-B inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers, including pancreatic cancer.

General Information

NCT#: NCT03678883
Study ID: 1801
Trial Phase: Phase I/II

Trial Sponsor: Actuate Therapeutics Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Irinotecan, Carboplatin, Paclitaxel, Doxorubicin, 9-ING-41, lomustine

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search